Registry for patients with hereditary bleeding vessel disease (HHT)
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation clinical trials.
This is a patient registry that collects information about people with hereditary hemorrhagic telangiectasia (HHT). It may help doctors better understand the condition and improve care over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HHT (hereditary bleeding vessel disease).
- You receive your care or follow-up through the HHT clinic (Unidad HHT) at Hospital Italiano de Buenos Aires.
- You are willing to participate in the registry.
- You agree to the consent process (you do not refuse participation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects health information from people with HHT over time to better understand the disease and improve care. Joining does not involve any experimental treatment, but your data will help researchers learn more about HHT.
This study looks at DNA (genetic material) in families affected by hereditary hemorrhagic telangiectasia (HHT). It aims to understand the genetic basis of HHT and why it runs in families.
This study reviews past medical records (case notes) from people with hereditary hemorrhagic telangiectasia (HHT). It helps researchers understand patterns of care and outcomes, without requiring new treatment for you.
This study uses an echocardiogram (a heart ultrasound) to look for possible heart problems in people with hereditary hemorrhagic telangiectasia (HHT). It will help doctors understand how HHT affects the heart.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
Hear when a new Haemorrhagic Hereditary Telangiectasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.